526 related articles for article (PubMed ID: 17085199)
1. Prognostic value of DNA ploidy, bcl-2 and p53 in localized prostate adenocarcinoma incidentally discovered at transurethral prostatectomy.
Abaza R; Diaz LK; Laskin WB; Pins MR
J Urol; 2006 Dec; 176(6 Pt 1):2701-5. PubMed ID: 17085199
[TBL] [Abstract][Full Text] [Related]
2. p53, bcl-2 and retinoblastoma proteins as long-term prognostic markers in localized carcinoma of the prostate.
Theodorescu D; Broder SR; Boyd JC; Mills SE; Frierson HF
J Urol; 1997 Jul; 158(1):131-7. PubMed ID: 9186339
[TBL] [Abstract][Full Text] [Related]
3. Preoperative p53, bcl-2, CD44 and E-cadherin immunohistochemistry as predictors of biochemical relapse after radical prostatectomy.
Brewster SF; Oxley JD; Trivella M; Abbott CD; Gillatt DA
J Urol; 1999 Apr; 161(4):1238-43. PubMed ID: 10081877
[TBL] [Abstract][Full Text] [Related]
4. Apoptotic and mitotic indices predict survival rates in lymph node-negative colon carcinomas.
Sinicrope FA; Hart J; Hsu HA; Lemoine M; Michelassi F; Stephens LC
Clin Cancer Res; 1999 Jul; 5(7):1793-804. PubMed ID: 10430084
[TBL] [Abstract][Full Text] [Related]
5. Expression of biomarkers modulating prostate cancer progression: implications in the treatment of the disease.
Di Lorenzo G; De Placido S; Autorino R; De Laurentiis M; Mignogna C; D'Armiento M; Tortora G; De Rosa G; D'Armiento M; De Sio M; Bianco AR; D'Armiento FP
Prostate Cancer Prostatic Dis; 2005; 8(1):54-9. PubMed ID: 15655565
[TBL] [Abstract][Full Text] [Related]
6. Quantitative nuclear morphometry, Markovian texture descriptors, and DNA content captured on a CAS-200 Image analysis system, combined with PCNA and HER-2/neu immunohistochemistry for prediction of prostate cancer progression.
Veltri RW; Partin AW; Epstein JE; Marley GM; Miller CM; Singer DS; Patton KP; Criley SR; Coffey DS
J Cell Biochem Suppl; 1994; 19():249-58. PubMed ID: 7529856
[TBL] [Abstract][Full Text] [Related]
7. Elevated levels of apoptosis regulator proteins p53 and bcl-2 are independent prognostic biomarkers in surgically treated clinically localized prostate cancer.
Bauer JJ; Sesterhenn IA; Mostofi FK; McLeod DG; Srivastava S; Moul JW
J Urol; 1996 Oct; 156(4):1511-6. PubMed ID: 8808919
[TBL] [Abstract][Full Text] [Related]
8. Prognostic significance of Bcl-2 in clinically localized prostate cancer.
Bubendorf L; Sauter G; Moch H; Jordan P; Blöchlinger A; Gasser TC; Mihatsch MJ
Am J Pathol; 1996 May; 148(5):1557-65. PubMed ID: 8623924
[TBL] [Abstract][Full Text] [Related]
9. Prostate stem cell antigen mRNA expression in preoperatively negative biopsy specimens predicts subsequent cancer after transurethral resection of the prostate for benign prostatic hyperplasia.
Zhao Z; Liu J; Li S; Shen W
Prostate; 2009 Sep; 69(12):1292-302. PubMed ID: 19462463
[TBL] [Abstract][Full Text] [Related]
10. Flow cytometric determination of ploidy in prostatic adenocarcinoma and its relation to clinical outcome.
Blatstein LM; Ginsberg PC; Daskal I; Finkelstein LH
J Am Osteopath Assoc; 1993 Apr; 93(4):463-8, 471-2. PubMed ID: 8478220
[TBL] [Abstract][Full Text] [Related]
11. Immunohistochemical expression of Ki-67 antigen, cox-2 and Bax/Bcl-2 in prostate cancer; prognostic value in biopsies and radical prostatectomy specimens.
Rubio J; Ramos D; López-Guerrero JA; Iborra I; Collado A; Solsona E; Almenar S; Llombart-Bosch A
Eur Urol; 2005 Nov; 48(5):745-51. PubMed ID: 16139948
[TBL] [Abstract][Full Text] [Related]
12. Predictive value of decreased p27Kip1 protein expression for the recurrence-free and long-term survival of prostate cancer patients.
Kuczyk M; Machtens S; Hradil K; Schubach J; Christian W; Knüchel R; Hartmann J; Bokemeyer C; Jonas U; Serth J
Br J Cancer; 1999 Nov; 81(6):1052-8. PubMed ID: 10576664
[TBL] [Abstract][Full Text] [Related]
13. Prognostic factors in prostate cancer.
Stattin P
Scand J Urol Nephrol Suppl; 1997; 185():1-46. PubMed ID: 9249905
[TBL] [Abstract][Full Text] [Related]
14. DNA ploidy and proliferation heterogeneity in human prostate cancers.
Shankey TV; Jin JK; Dougherty S; Flanigan RC; Graham S; Pyle JM
Cytometry; 1995 Sep; 21(1):30-9. PubMed ID: 8529468
[TBL] [Abstract][Full Text] [Related]
15. Utility of Bcl-2, P53, Ki-67, and caveolin-1 immunostaining in the prediction of biochemical failure after radical prostatectomy in a Japanese population.
Goto T; Nguyen BP; Nakano M; Ehara H; Yamamoto N; Deguchi T
Urology; 2008 Jul; 72(1):167-71. PubMed ID: 18384856
[TBL] [Abstract][Full Text] [Related]
16. A DNA cytometric proliferation index improves the value of the DNA ploidy pattern as a prognosticating tool in patients with carcinoma of the prostate.
Ahlgren G; Lindholm K; Falkmer U; Abrahamsson PA
Urology; 1997 Sep; 50(3):379-84. PubMed ID: 9301701
[TBL] [Abstract][Full Text] [Related]
17. Subclassification of clinical stage T1 prostate cancer: impact on biochemical recurrence following radical prostatectomy.
Magheli A; Rais-Bahrami S; Carter HB; Peck HJ; Epstein JI; Gonzalgo ML
J Urol; 2007 Oct; 178(4 Pt 1):1277-80; discussion 1280-1. PubMed ID: 17698121
[TBL] [Abstract][Full Text] [Related]
18. Combined c-Myc and caveolin-1 expression in human prostate carcinoma predicts prostate carcinoma progression.
Yang G; Timme TL; Frolov A; Wheeler TM; Thompson TC
Cancer; 2005 Mar; 103(6):1186-94. PubMed ID: 15712208
[TBL] [Abstract][Full Text] [Related]
19. Radical prostatectomy for incidental (stage T1a-T1b) prostate cancer: analysis of predictors for residual disease and biochemical recurrence.
Capitanio U; Scattoni V; Freschi M; Briganti A; Salonia A; Gallina A; Colombo R; Karakiewicz PI; Rigatti P; Montorsi F
Eur Urol; 2008 Jul; 54(1):118-25. PubMed ID: 18314255
[TBL] [Abstract][Full Text] [Related]
20. Determining prognosis of clinically localized prostate cancer by immunohistochemical detection of mutant p53.
Stricker HJ; Jay JK; Linden MD; Tamboli P; Amin MB
Urology; 1996 Mar; 47(3):366-9. PubMed ID: 8633403
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]